Aspira Pathlab and Diagnostics Q4 FY26 Results: Loss Rs 0.69 Cr

Aspira Pathlab and Diagnostics Q4 FY26 results were declared on May 24, 2026. The company reported net loss of Rs 0.69 crore for the quarter ended March 31, 2026, down 297.1% YoY compared to Rs 0.35 crore in Q4 FY25. Results are on a Standalone basis. Aspira Pathlab and Diagnostics is a Diagnostics and Pathology company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Aspira Pathlab and Diagnostics Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Net Loss	0.69	0.35	-297.1%
Basis	Standalone

Note: Q4 FY26 standalone net loss Rs 0.69 crore vs profit Rs 0.35 crore in Q4 FY25. Diagnostics and pathology services. Verify from BSE/NSE audited filings before investment decisions.

Aspira Pathlab and Diagnostics Q4 FY26 Performance Analysis

The Aspira Pathlab and Diagnostics Q4 FY26 results reflect the company’s financial performance during the January to March 2026 quarter. The quarter reflects near-term profitability challenges. Aspira Pathlab and Diagnostics operates in the Diagnostics and Pathology sector, supported by India’s GDP growth above 6.5% in FY26.

The company’s profitability metrics reflect the core Diagnostics and Pathology business performance in Q4 FY26.

Screen the best stocks on the Univest Screener.

Key Factors Driving Aspira Pathlab and Diagnostics Q4 FY26 Results

Revenue and Business Performance

Aspira Pathlab and Diagnostics Q4 FY26 operational execution reflects the Diagnostics and Pathology business activities during January to March 2026. The January to March quarter is the fiscal year-end period characterised by strong order execution cycles.

Profitability and Margin Trends

The Aspira Pathlab and Diagnostics Q4 FY26 net loss of Rs 0.69 crore down 297.1% YoY. The net loss reflects ongoing operational challenges. Cost discipline and revenue recovery remain FY27 priorities.

India Macro Environment

India’s macro environment in Q4 FY26 was supportive with GDP growth above 6.5%, government capex of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption. The Diagnostics and Pathology sector benefited from these structural tailwinds during the January to March 2026 quarter.

FY27 Outlook

Following the firm results, management guidance on FY27 revenue growth, margin improvement, and capital allocation will be key investor watchpoints. Returning to profitability through operational improvements remains the key FY27 objective.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the company

Investments in securities are subject to market risk. This content is for educational purposes only. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.